Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

McCune JS, Wang T, Bo-Subait K, Aljurf M, Beitinjaneh A, Bubalo J, Cahn JY, Cerny J, Chhabra S, Cumpston A, Dupuis LL, Lazarus HM, Marks DI, Maziarz RT, Norkin M, Prestidge T, Mineishi S, Krem MM, Pasquini M, Martin PJ.

Biol Blood Marrow Transplant. 2019 Mar 11. pii: S1083-8791(19)30150-8. doi: 10.1016/j.bbmt.2019.03.001. [Epub ahead of print]

PMID:
30871976
2.

Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance.

Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y.

Front Immunol. 2019 Feb 1;10:93. doi: 10.3389/fimmu.2019.00093. eCollection 2019. Review.

3.

Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia.

Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Shike H, Bayerl MG, Sivik JM, Schell TD, Drabick JJ, Hohl RJ, Zheng H.

Cancer Res. 2019 Apr 1;79(7):1635-1645. doi: 10.1158/0008-5472.CAN-18-3107. Epub 2019 Feb 1.

PMID:
30709927
4.

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.

Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, Fretham C, Jacobsohn DA, Loren AW, Kurtzberg J, Martinez CA, Mineishi S, Nelson AS, Woolfrey A, Pasquini MC, Sorror ML.

Blood. 2019 Feb 14;133(7):754-762. doi: 10.1182/blood-2018-09-876284. Epub 2018 Dec 13.

PMID:
30545834
5.

Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation.

Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadalla SM, Gale RP, Ganguly S, Hashmi SK, Hematti P, Hildebrandt G, Holmberg LA, Lahoud OB, Landau H, Lazarus HM, de Lima M, Mathews V, Maziarz R, Nishihori T, Norkin M, Olsson R, Reshef R, Rotz S, Savani B, Schouten HC, Seo S, Wirk BM, Yared J, Mineishi S, Rogosheske J, Perales MA.

Biol Blood Marrow Transplant. 2019 Mar;25(3):480-487. doi: 10.1016/j.bbmt.2018.11.005. Epub 2018 Nov 10.

PMID:
30423481
6.

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H.

Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.

7.

Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.

Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, O'Brien T, Williams K, Pasquini MC, Levine JE.

Blood Adv. 2018 Jun 12;2(11):1198-1206. doi: 10.1182/bloodadvances.2018016956.

8.

Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.

Saad A, Taneja A, Di Stasi A, Sarmad R, Kukkamalla R, Costa L, Salzman D, Innis-Shelton R, Chewning JH, Meredith RF, Hauptfeld V, Langford S, Plessala K, Bhatia R, Lamb LS, Mineishi S.

Bone Marrow Transplant. 2018 Oct;53(10):1345-1348. doi: 10.1038/s41409-018-0185-6. Epub 2018 May 4. No abstract available.

PMID:
29728698
9.

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H.

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4. No abstract available.

10.

Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.

Rakszawski K, Miki K, Claxton D, Wagner H, Shike H, Mineishi S, Naik S.

Int J Hematol. 2018 Sep;108(3):348-350. doi: 10.1007/s12185-018-2431-5. Epub 2018 Mar 14.

PMID:
29542029
11.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

12.

Hematopoietic stem cell transplantation in the era of molecular targeted therapy.

Mineishi S.

Rinsho Ketsueki. 2017;58(10):2135-2140. doi: 10.11406/rinketsu.58.2135. Japanese.

PMID:
28978858
13.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM.

Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.

14.

Late-Onset Cerebral Toxoplasmosis After Allogeneic Hematopoietic Stem Cell Transplantation.

Khalaf AM, Hashim MA, Alsharabati M, Fallon K, Cure JK, Pappas P, Mineishi S, Saad A.

Am J Case Rep. 2017 Mar 10;18:246-250.

15.

Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.

PLoS One. 2017 Feb 15;12(2):e0172640. doi: 10.1371/journal.pone.0172640. eCollection 2017.

16.

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.

PLoS One. 2016 Dec 1;11(12):e0166891. doi: 10.1371/journal.pone.0166891. eCollection 2016. Erratum in: PLoS One. 2017 Feb 15;12 (2):e0172640.

17.

Update on stem cell transplantation for acute leukemias.

Mineishi S.

Rinsho Ketsueki. 2016;57(10):2218-2223. Japanese.

PMID:
27795533
18.

Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure.

Aboul Nour H, Patil N, Chewning JH, Di Stasi A, Salzman D, Innis-Shelton R, Lamb L, Mineishi S, Saad A.

Bone Marrow Transplant. 2017 Jan;52(1):157-158. doi: 10.1038/bmt.2016.208. Epub 2016 Aug 15. No abstract available.

PMID:
27526281
19.

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.

Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S.

Bone Marrow Transplant. 2017 Jan;52(1):59-65. doi: 10.1038/bmt.2016.188. Epub 2016 Jul 18.

20.

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.

Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1424-1430. doi: 10.1016/j.bbmt.2016.04.013. Epub 2016 May 3.

21.

Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.

Mochizuki K, Meng L, Mochizuki I, Tong Q, He S, Liu Y, Purushe J, Fung H, Zaidi MR, Zhang Y, Reshef R, Blazar BR, Yagita H, Mineishi S, Zhang Y.

Blood. 2016 Jun 23;127(25):3270-80. doi: 10.1182/blood-2015-05-644476. Epub 2016 May 3.

22.

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher MA, Bence-Bruckler I, Laneuville P, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1197-1205. doi: 10.1016/j.bbmt.2016.03.018. Epub 2016 Mar 31.

23.

Reply to a note on the magnitude of hazard ratios.

Borate UM, Mineishi S, Costa LJ.

Cancer. 2016 Apr 15;122(8):1299-300. doi: 10.1002/cncr.29923. Epub 2016 Feb 16. No abstract available.

24.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ.

Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29.

25.

Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

Al Malki MM, Horowitz M, Handgretinger R, Leung W, Roy DC, Huang XJ, Fuchs E, Locatelli F, Blaise D, Mineishi S, Martelli M, Miller J, June C, Ai HS, Luznik L, Mavilio D, Lugli E, van den Brink MRM, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2016 Apr;22(4):594-604. doi: 10.1016/j.bbmt.2016.01.001. Epub 2016 Jan 13.

26.

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation.

Meng L, Bai Z, He S, Mochizuki K, Liu Y, Purushe J, Sun H, Wang J, Yagita H, Mineishi S, Fung H, Yanik GA, Caricchio R, Fan X, Crisalli LM, Hexner EO, Reshef R, Zhang Y, Zhang Y.

J Immunol. 2016 Feb 1;196(3):1070-80. doi: 10.4049/jimmunol.1501310. Epub 2015 Dec 28.

27.

Acute myofascitis as a manifestation of chronic graft-versus-host disease.

Khan M, Ubogu E, Alsharabati M, Salzman D, Mineishi S, Saad A.

Muscle Nerve. 2016 Feb;53(2):327-9. doi: 10.1002/mus.24937. Epub 2015 Nov 26. No abstract available.

PMID:
26474295
28.

Nonbiological factors affecting survival in younger patients with acute myeloid leukemia.

Borate UM, Mineishi S, Costa LJ.

Cancer. 2015 Nov 1;121(21):3877-84. doi: 10.1002/cncr.29436. Epub 2015 Sep 14.

29.

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.

Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR.

Biol Blood Marrow Transplant. 2016 Jan;22(1):54-60. doi: 10.1016/j.bbmt.2015.07.021. Epub 2015 Jul 26.

30.

Seatbelts in CAR therapy: How Safe Are CARS?

Minagawa K, Zhou X, Mineishi S, Di Stasi A.

Pharmaceuticals (Basel). 2015 May 8;8(2):230-49. doi: 10.3390/ph8020230. Review.

31.

State-of-the-art acute and chronic GVHD treatment.

Jamil MO, Mineishi S.

Int J Hematol. 2015 May;101(5):452-66. doi: 10.1007/s12185-015-1785-1. Epub 2015 Apr 12. Review.

PMID:
25864189
32.

Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.

Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC.

Ann Hematol. 2015 Jun;94(6):1033-41. doi: 10.1007/s00277-015-2349-4. Epub 2015 Mar 19.

PMID:
25784222
33.

Telomere length in hematopoietic stem cell transplantation for severe aplastic anemia: is it ready for "prime time"?

Saad A, Mineishi S, Innis-Shelton R.

JAMA. 2015 Feb 10;313(6):571-2. doi: 10.1001/jama.2015.8. No abstract available.

PMID:
25668259
34.

Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.

Innis-Shelton RD, Davis RS, Lamb L, Mineishi S.

Leuk Lymphoma. 2015 Jun;56(6):1626-35. doi: 10.3109/10428194.2014.974041. Epub 2015 Jan 8. Review.

PMID:
25308292
35.

Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.

Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti C.

J Clin Oncol. 2014 Aug 1;32(22):2365-72. doi: 10.1200/JCO.2013.54.4577. Epub 2014 Jun 30.

36.

The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.

He S, Xie F, Liu Y, Tong Q, Mochizuki K, Lapinski PE, Mani RS, Reddy P, Mochizuki I, Chinnaiyan AM, Mineishi S, King PD, Zhang Y.

Blood. 2013 Dec 12;122(25):4119-28. doi: 10.1182/blood-2013-05-505180. Epub 2013 Oct 18.

37.

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.

Richardson PG, Ho VT, Giralt S, Arai S, Mineishi S, Cutler C, Antin JH, Stavitzski N, Niederwieser D, Holler E, Carreras E, Soiffer R.

Ther Adv Hematol. 2012 Aug;3(4):253-65. doi: 10.1177/2040620712441943.

38.

Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice.

Mochizuki K, Xie F, He S, Tong Q, Liu Y, Mochizuki I, Guo Y, Kato K, Yagita H, Mineishi S, Zhang Y.

J Immunol. 2013 Apr 1;190(7):3772-82. doi: 10.4049/jimmunol.1202820. Epub 2013 Feb 25.

39.

Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.

Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, St Clair EW, Furst DE, Khanna D, Forman S, Mineishi S, Phillips K, Seibold JR, Bredeson C, Csuka ME, Nash RA, Wener MH, Simms R, Ballen K, Leclercq S, Storek J, Goldmuntz E, Welch B, Keyes-Elstein L, Castina S, Crofford LJ, Mcsweeney P, Sullivan KM.

J Rheumatol. 2013 Apr;40(4):455-60. doi: 10.3899/jrheum.121087. Epub 2013 Feb 15.

40.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network.

N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517.

41.

Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes.

Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE.

Haematologica. 2013 Feb;98(2):179-84. doi: 10.3324/haematol.2012.073189. Epub 2012 Oct 12.

42.

TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.

Choi SW, Stiff P, Cooke K, Ferrara JL, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1525-32. doi: 10.1016/j.bbmt.2012.03.013. Epub 2012 Mar 30.

43.

Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.

Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1044-54. doi: 10.1016/j.bbmt.2011.11.031. Epub 2011 Dec 10.

44.

Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.

He S, Wang J, Kato K, Xie F, Varambally S, Mineishi S, Kuick R, Mochizuki K, Liu Y, Nieves E, Mani RS, Chinnaiyan AM, Marquez VE, Zhang Y.

Blood. 2012 Feb 2;119(5):1274-82. doi: 10.1182/blood-2011-06-364422. Epub 2011 Nov 23.

45.

Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.

Mineishi S.

JAMA. 2011 Nov 2;306(17):1918-20. doi: 10.1001/jama.2011.1612. No abstract available.

PMID:
22045771
46.

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.

Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S.

Blood. 2011 Oct 13;118(15):4258-64. doi: 10.1182/blood-2011-06-358010. Epub 2011 Aug 12.

47.

Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells.

He S, Kato K, Jiang J, Wahl DR, Mineishi S, Fisher EM, Murasko DM, Glick GD, Zhang Y.

PLoS One. 2011;6(5):e20107. doi: 10.1371/journal.pone.0020107. Epub 2011 May 17.

48.

Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.

Hosing C, Nash R, McSweeney P, Mineishi S, Seibold J, Griffith LM, Shulman H, Goldmuntz E, Mayes M, Parikh CR, Crofford L, Keyes-Elstein L, Furst D, Steen V, Sullivan KM.

Biol Blood Marrow Transplant. 2011 May;17(5):674-81. doi: 10.1016/j.bbmt.2010.08.003. Epub 2010 Aug 11.

49.

Elafin is a biomarker of graft-versus-host disease of the skin.

Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, Olsen S, Choi SW, Wang H, Faca V, Pitteri S, Zhang Q, Chin A, Kitko C, Mineishi S, Yanik G, Peres E, Hanauer D, Wang Y, Reddy P, Hanash S, Ferrara JL.

Sci Transl Med. 2010 Jan 6;2(13):13ra2. doi: 10.1126/scitranslmed.3000406.

50.

Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.

Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S.

Biol Blood Marrow Transplant. 2010 Jul;16(7):907-14. doi: 10.1016/j.bbmt.2010.02.026. Epub 2010 Mar 17.

Supplemental Content

Loading ...
Support Center